Theranexus SA (PA:ALTHX) — Market Cap & Net Worth
Market Cap & Net Worth: Theranexus SA (ALTHX)
Theranexus SA (PA:ALTHX) has a market capitalization of $45.64 Million (€39.03 Million) as of August 4, 2026. Listed on the PA stock exchange, this France-based company holds position #22193 globally and #348 in its home market, demonstrating a 13.56% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theranexus SA's stock price €4.27 by its total outstanding shares 14441625 (14.44 Million). See capital reinvestment ratio of Theranexus SA to understand how much of operating cash flow is reinvested back into capital assets.
Theranexus SA Market Cap History: 2017 to 2026
Theranexus SA's market capitalization history from 2017 to 2026. Data shows change from $250.72 Million to $72.09 Million (-13.74% CAGR).
Theranexus SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theranexus SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.27x
Theranexus SA's market cap is 4.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $250.72 Million | $147.83K | -$2.11 Million | 1696.01x | N/A |
| 2018 | $302.56 Million | $110.93K | -$5.30 Million | 2727.49x | N/A |
| 2019 | $51.33 Million | $563.85K | -$5.58 Million | 91.03x | N/A |
| 2020 | $314.88 Million | $294.61K | -$4.80 Million | 1068.81x | N/A |
| 2021 | $83.57 Million | $602.00 | -$8.15 Million | 138828.40x | N/A |
| 2022 | $29.55 Million | $414.90K | -$6.57 Million | 71.21x | N/A |
| 2023 | $18.91 Million | $296.33K | -$6.83 Million | 63.81x | N/A |
| 2024 | $9.76 Million | $2.28 Million | -$1.77 Million | 4.27x | N/A |
Competitor Companies of ALTHX by Market Capitalization
Companies near Theranexus SA in the global market cap rankings as of August 4, 2026.
Key companies related to Theranexus SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Theranexus SA Historical Marketcap From 2017 to 2026
Between 2017 and today, Theranexus SA's market cap moved from $250.72 Million to $ 72.09 Million, with a yearly change of -13.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €72.09 Million | +99.53% |
| 2025 | €36.13 Million | +270.24% |
| 2024 | €9.76 Million | -48.39% |
| 2023 | €18.91 Million | -36.00% |
| 2022 | €29.55 Million | -64.65% |
| 2021 | €83.57 Million | -73.46% |
| 2020 | €314.88 Million | +513.49% |
| 2019 | €51.33 Million | -83.04% |
| 2018 | €302.56 Million | +20.67% |
| 2017 | €250.72 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Theranexus SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.64 Million USD |
| MoneyControl | $45.64 Million USD |
| MarketWatch | $45.64 Million USD |
| marketcap.company | $45.64 Million USD |
| Reuters | $45.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more